Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Q1 2023 YUPELRI® (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 20221 Q1 2023 YUPELRI retail new patient starts and total prescriptions up 61% and 29%, respectively, year-over-year, reaching all-time highs2 CYPRESS Phase 3 study of ampreloxetine recruiting;...